Brief: Nevro Responds To Competitor's Announcement Of FDA Approval For Painful Diabetic Neuropathy
25/01/2022 14:30
Jan 25 (Reuters) - Nevro Corp NVRO.N :
* NEVRO RESPONDS TO COMPETITOR'S ANNOUNCEMENT OF FDA
APPROVAL FOR
PAINFUL DIABETIC NEUROPATHY
Source text for Eikon: ID:nPn4Mq24pa
Further company coverage: NVRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nevro
See all newsNevro Corp reports results for the quarter ended December 31 - Earnings Summary
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro